• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

根治性前列腺切除术和淋巴结清扫术在骨转移前列腺癌中的作用:一项基于人群的研究。

The role of cytoreductive radical prostatectomy and lymph node dissection in bone-metastatic prostate cancer: A population-based study.

机构信息

Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China.

出版信息

Cancer Med. 2023 Aug;12(16):16697-16706. doi: 10.1002/cam4.6292. Epub 2023 Jun 27.

DOI:10.1002/cam4.6292
PMID:37366247
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10501265/
Abstract

BACKGROUNDS

The role of cytoreductive radical prostatectomy (cRP) for bone-metastatic prostate cancer (bmPCa) remains controversial. We aimed to figure out whether cRP and lymph node dissection (LND) can benefit bmPCa.

METHODS

11,271 PCa patients with bone metastatic burden from 2010 to 2019 were identified using SEER-Medicare. Overall survival (OS) and cancer-specific survival (CSS) rates were visualized using Kaplan-Meier plots. Multivariable Cox regression analyses were constructed to examine the effects of cRP and LND on survival, after stratifying to age, prostate specific antigen (PSA), clinical stages, Gleason score, metastatic burden, radiotherapy, and chemotherapy status.

RESULTS

317 PCa patients underwent cRP and cRP was increasingly performed for bmPCa from 2010 (2.2%) to 2019 (3.0%) (p < 0.05). In multi analyses, cRP was predisposed to a better OS or CSS in patients with age < 75, PSA < 98 ng/mL, bone-only metastatic sites or patients not receiving chemotherapy (all p < 0.05). For the patients undergoing cRP, LND especially extended LND was associated with a better OS or CSS (all p < 0.05).

CONCLUSIONS

cRP might benefit OS or CSS in young patients with low PSA and bone-only metastatic sites not receiving chemotherapy. And a clear OS or CSS benefit of LND especially extended LND was observed in patients undergoing cRP.

摘要

背景

对于骨转移前列腺癌(bmPCa),细胞减灭性前列腺切除术(cRP)的作用仍存在争议。我们旨在探讨 cRP 和淋巴结清扫(LND)是否对 bmPCa 有益。

方法

使用 SEER-Medicare 确定了 2010 年至 2019 年间有骨转移负担的 11271 例前列腺癌患者。使用 Kaplan-Meier 图可视化总生存(OS)和癌症特异性生存(CSS)率。在分层考虑年龄、前列腺特异性抗原(PSA)、临床分期、Gleason 评分、转移负担、放疗和化疗状态后,构建多变量 Cox 回归分析以检查 cRP 和 LND 对生存的影响。

结果

317 例前列腺癌患者接受了 cRP,并且从 2010 年(2.2%)到 2019 年(3.0%),cRP 越来越多地用于 bmPCa(p<0.05)。在多因素分析中,在年龄<75 岁、PSA<98ng/mL、仅有骨转移部位或未接受化疗的患者中,cRP 有利于更好的 OS 或 CSS(均 p<0.05)。对于接受 cRP 的患者,LND 尤其是广泛 LND 与更好的 OS 或 CSS 相关(均 p<0.05)。

结论

在未接受化疗且 PSA 低和仅有骨转移部位的年轻患者中,cRP 可能有益于 OS 或 CSS。在接受 cRP 的患者中,LND 尤其是广泛 LND 明显有益于 OS 或 CSS。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf1/10501265/8570bec501c2/CAM4-12-16697-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf1/10501265/a7e0b64b177d/CAM4-12-16697-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf1/10501265/bfbf05c6bc8d/CAM4-12-16697-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf1/10501265/8570bec501c2/CAM4-12-16697-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf1/10501265/a7e0b64b177d/CAM4-12-16697-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf1/10501265/bfbf05c6bc8d/CAM4-12-16697-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbf1/10501265/8570bec501c2/CAM4-12-16697-g002.jpg

相似文献

1
The role of cytoreductive radical prostatectomy and lymph node dissection in bone-metastatic prostate cancer: A population-based study.根治性前列腺切除术和淋巴结清扫术在骨转移前列腺癌中的作用:一项基于人群的研究。
Cancer Med. 2023 Aug;12(16):16697-16706. doi: 10.1002/cam4.6292. Epub 2023 Jun 27.
2
The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative Outcomes.根治性前列腺切除术治疗转移性前列腺癌患者淋巴结清扫的影响:生存和术后早期结局的当代分析。
Eur Urol Oncol. 2019 Sep;2(5):541-548. doi: 10.1016/j.euo.2018.10.010. Epub 2018 Nov 22.
3
Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases.去势根治性前列腺切除术治疗伴骨转移的前列腺癌男性患者。
Eur Urol Oncol. 2018 May;1(1):46-53. doi: 10.1016/j.euo.2018.03.002. Epub 2018 May 15.
4
Head-to-head comparison of lymph node density and number of positive lymph nodes in stratifying the outcome of patients with lymph node-positive prostate cancer submitted to radical prostatectomy and extended lymph node dissection.在接受根治性前列腺切除术和扩大淋巴结清扫术的淋巴结阳性前列腺癌患者中,对淋巴结密度和阳性淋巴结数量进行分层,以比较其结局的头对头比较。
Urol Oncol. 2014 Jan;32(1):29.e21-8. doi: 10.1016/j.urolonc.2012.10.009. Epub 2013 Mar 13.
5
Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years.对于临床复发的前列腺癌患者行挽救性淋巴结清扫术的长期疗效:单机构系列研究结果,随访时间至少 5 年。
Eur Urol. 2015 Feb;67(2):299-309. doi: 10.1016/j.eururo.2014.02.011. Epub 2014 Feb 18.
6
Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.根治性前列腺切除术是治疗标本中存在高病理 Gleason 评分前列腺癌的有效方法。
BJU Int. 2013 May;111(5):723-30. doi: 10.1111/j.1464-410X.2012.11114.x. Epub 2012 Apr 4.
7
Risk of lymph node metastases in pathological gleason score≤6 prostate adenocarcinoma: Analysis of institutional and population-based databases.病理Gleason评分≤6的前列腺腺癌发生淋巴结转移的风险:基于机构和人群数据库的分析
Urol Oncol. 2017 Jan;35(1):31.e1-31.e6. doi: 10.1016/j.urolonc.2016.08.004. Epub 2016 Sep 28.
8
Selective lymph node dissection for castration-resistant prostate cancer.去势抵抗性前列腺癌的选择性淋巴结清扫术。
Urol Int. 2012;88(4):441-6. doi: 10.1159/000335206. Epub 2012 Mar 7.
9
Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.根治性前列腺切除术改善了 PSA 时代淋巴结阳性前列腺癌男性的无进展生存期和癌症特异性生存期:一项确认性研究。
BJU Int. 2011 Jun;107(11):1755-61. doi: 10.1111/j.1464-410X.2010.09730.x. Epub 2010 Oct 13.
10
The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.根治性前列腺切除术后前列腺特异性抗原持续存在对预测淋巴结阳性前列腺癌患者临床进展和癌症特异性死亡率的作用。
Eur Urol. 2016 Jun;69(6):1142-8. doi: 10.1016/j.eururo.2015.12.010. Epub 2015 Dec 31.

引用本文的文献

1
Advances in prostate-specific membrane antigen-targeted theranostics: from radionuclides to near-infrared fluorescence technology.前列腺特异性膜抗原靶向诊疗技术的进展:从放射性核素到近红外荧光技术
Front Immunol. 2025 Jan 10;15:1533532. doi: 10.3389/fimmu.2024.1533532. eCollection 2024.
2
Current Controversy and Developments Regarding the Cytoreductive Prostatectomy for Oligometastatic Prostate Cancer.当前关于寡转移前列腺癌去神经前列腺切除术的争议和进展。
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231216011. doi: 10.1177/15330338231216011.

本文引用的文献

1
Cytoreductive Radical Prostatectomy for Metastatic Hormone-sensitive Prostate Cancer-Evidence from Recent Prospective Reports.根治性前列腺切除术治疗转移性激素敏感型前列腺癌:来自近期前瞻性报告的证据。
Eur Urol Focus. 2023 Jul;9(4):637-641. doi: 10.1016/j.euf.2023.01.011. Epub 2023 Jan 23.
2
The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer.转移性前列腺癌的细胞减灭性前列腺切除术:各试验希望回答的问题。
BJU Int. 2020 Jun;125(6):792-800. doi: 10.1111/bju.15055. Epub 2020 Apr 7.
3
Considering the role of radical prostatectomy in 21st century prostate cancer care.
考虑在 21 世纪前列腺癌治疗中根治性前列腺切除术的作用。
Nat Rev Urol. 2020 Mar;17(3):177-188. doi: 10.1038/s41585-020-0287-y. Epub 2020 Feb 21.
4
Cancer statistics, 2020.癌症统计数据,2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
5
Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases.去势根治性前列腺切除术治疗伴骨转移的前列腺癌男性患者。
Eur Urol Oncol. 2018 May;1(1):46-53. doi: 10.1016/j.euo.2018.03.002. Epub 2018 May 15.
6
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.新诊断转移性前列腺癌原发肿瘤放疗(STAMPEDE):一项随机对照 3 期试验。
Lancet. 2018 Dec 1;392(10162):2353-2366. doi: 10.1016/S0140-6736(18)32486-3. Epub 2018 Oct 21.
7
What Do the Guidelines Say for Metastatic Prostate Cancer Starting Androgen Deprivation Therapy? National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology recommendations.转移性前列腺癌开始雄激素剥夺治疗的指南有哪些建议?美国国家综合癌症网络、欧洲肿瘤内科学会和欧洲泌尿外科学会的建议。
Eur Urol Focus. 2019 Mar;5(2):162-164. doi: 10.1016/j.euf.2018.09.015. Epub 2018 Oct 2.
8
Landmarks in prostate cancer.前列腺癌的标志物。
Nat Rev Urol. 2018 Oct;15(10):627-642. doi: 10.1038/s41585-018-0060-7.
9
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.局部晚期和转移性前列腺癌的系统治疗进展:精准肿瘤学时代下转移性去势抵抗性前列腺癌的管理。
Eur Urol. 2019 Jan;75(1):88-99. doi: 10.1016/j.eururo.2018.03.028. Epub 2018 Apr 16.
10
Reconsidering the role of pelvic lymph node dissection with radical prostatectomy for prostate cancer in an era of improving radiological staging techniques.在放射影像学分期技术不断进步的时代,重新思考根治性前列腺切除术时行盆腔淋巴结清扫术在前列腺癌中的作用。
World J Urol. 2018 Jan;36(1):15-20. doi: 10.1007/s00345-017-2119-0. Epub 2017 Nov 7.